Compare CellaVision AB with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROE of 19.18%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 15.75
3
Poor long term growth as Operating profit has grown by an annual rate 12.88% of over the last 5 years
4
With ROE of 17.25%, it has a attractive valuation with a 4.01 Price to Book Value
5
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
6
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
SEK 2,886 Million (Small Cap)
23.00
NA
0.03%
-0.23
14.66%
3.16
Revenue and Profits:
Net Sales:
166 Million
(Quarterly Results - Mar 2026)
Net Profit:
23 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-20.4%
0%
-20.4%
6 Months
-25.16%
0%
-25.16%
1 Year
-38.23%
0%
-38.23%
2 Years
-50.53%
0%
-50.53%
3 Years
-33.74%
0%
-33.74%
4 Years
-61.1%
0%
-61.1%
5 Years
-66.18%
0%
-66.18%
CellaVision AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.99%
EBIT Growth (5y)
12.88%
EBIT to Interest (avg)
15.75
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.19
Sales to Capital Employed (avg)
0.87
Tax Ratio
20.41%
Dividend Payout Ratio
42.85%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
26.30%
ROE (avg)
19.18%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
4.01
EV to EBIT
16.83
EV to EBITDA
14.21
EV to Capital Employed
4.69
EV to Sales
4.48
PEG Ratio
2.65
Dividend Yield
0.01%
ROCE (Latest)
27.87%
ROE (Latest)
17.25%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Dec 2016
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
166.40
194.80
-14.58%
Operating Profit (PBDIT) excl Other Income
39.90
66.50
-40.00%
Interest
0.50
5.20
-90.38%
Exceptional Items
0.00
0.00
Consolidate Net Profit
22.50
41.50
-45.78%
Operating Profit Margin (Excl OI)
171.20%
293.20%
-12.20%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is -14.58% vs 14.52% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -45.78% vs 37.87% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
759.00
723.20
4.95%
Operating Profit (PBDIT) excl Other Income
241.40
218.70
10.38%
Interest
0.90
1.90
-52.63%
Exceptional Items
0.00
0.00
Consolidate Net Profit
153.10
140.70
8.81%
Operating Profit Margin (Excl OI)
266.20%
245.70%
2.05%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 4.95% vs 6.78% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 8.81% vs 7.98% in Dec 2024
About CellaVision AB 
CellaVision AB
Pharmaceuticals & Biotechnology
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
Company Coordinates 
Company Details
Mobilvagen 12 , LUND None : 223 62
Registrar Details






